BioMarin Pharmaceutical Inc

Common Name
BioMarin Pharmaceutical
Country
United States
Sector
Healthcare
Industry
Biotechnology
Employees
3,040
Ticker
BMRN
Exchange
NASDAQ/NGS
Description
BioMarin Pharmaceutical Inc. is a leading biotechnology company specializing in the development and commercialization of innovative therapies for rare genetic diseases. Established in 1997 and headqua...

BioMarin Pharmaceutical's GHG Emissions Data Preview

In 2022, BioMarin Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), and Scope 2 (indirect emissions from purchased energy).

However, BioMarin Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)2024202320222021 - 2017
Total Scope 1
0000000
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 2
Location-Based
0000000
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 3
0000000
Copy restricted. Please purchase to unlock this data.
Copy restricted. Please purchase to unlock this data.
0000000

This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.

Insights into BioMarin Pharmaceutical's Operational Emissions

In 2022, the total operational greenhouse gas (GHG) emissions of BioMarin Pharmaceutical amounted to 23,000 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).

0

BioMarin Pharmaceutical's Scope 1 Emissions Over Time

20202021202204 k8 k12 k16 ktCO2e0%-7%
  • Total Scope 1
  • Year-over-Year Change

What are BioMarin Pharmaceutical's Scope 1 emissions?

In 2022, the total Scope 1 emissions of BioMarin Pharmaceutical were 14,000 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).

Has BioMarin Pharmaceutical reduced its Scope 1 emissions over time?

Since 2020, BioMarin Pharmaceutical's Scope 1 emissions have decreased by 6.67%, reflecting a declining long-term trend in Scope 1 emissions over time.

Compared to the previous year (2021), BioMarin Pharmaceutical's Scope 1 emissions decreased by 6.67%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.

What are BioMarin Pharmaceutical's Scope 2 emissions?

In 2022, BioMarin Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 9,000 tCOâ‚‚e using the location-based method.

Has BioMarin Pharmaceutical reduced its Scope 2 emissions over time?

Since 2020, BioMarin Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have increased by 28.57%, reflecting a rising long-term trend in Scope 2 emissions over time.

Compared to the previous year (2021), BioMarin Pharmaceutical's Scope 2 emissions (Location-Based) rose by 12.5% in 2022, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy

What methodology does BioMarin Pharmaceutical use for Scope 2 reporting?

In 2022, BioMarin Pharmaceutical reported its Scope 2 emissions using the location-based method.

BioMarin Pharmaceutical's Scope 2 Emissions Over Time

20202021202202.5 k5 k7.5 k10 ktCO2e
  • Total Scope 2 Location-Based
Want Full Access to BioMarin Pharmaceutical's GHG Emissions Dataset?
Sign Up